SBG004
Postoperative Pain
Pre-clinical/Phase 1Active
Key Facts
About Sonoran Biosciences
Sonoran Biosciences is a Scottsdale-based biotech founded in 2018, targeting two major unmet needs in surgical care: postoperative pain and surgical site infection (SSI). The company's core technology is the SB Gel, a biomaterial platform for localized, sustained drug release. Its lead candidates are SBG004, a sustained-release local anesthetic for pain, and SBG003, a sustained-release antimicrobial for SSI prevention, with both programs in development and supported by NIH SBIR funding.
View full company profileTherapeutic Areas
Other Postoperative Pain Drugs
| Drug | Company | Phase |
|---|---|---|
| Alevatrix™ | Rebel Medicine | IND-enabling |
| TT5 | Tafalgie Therapeutics | Phase 1 |
| LT1001 | Lumosa Therapeutics | Market |